CLINICAL STUDY: HYPERTROPHIC CARDIOMYOPATHY
Development of left ventricular hypertrophy in adults with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations
Barry J. Maron, MD, FACC*,
Hideshi Niimura, MD ,
Susan A. Casey, RN ,
Marjorie K. Soper, MD,
Gregory B. Wright, MD, FACC,
J. G. Seidman, PhD and
Christine E. Seidman, MD
* Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA
First Department of Internal Medicine, Kagoshima University, Kagoshima, Japan
Children’s Heart Clinic, Minneapolis, Minnesota, USA
Howard Hughes Medical Institute and Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA
Manuscript received September 21, 2000;
revised manuscript received March 19, 2001,
accepted April 12, 2001.
Reprint requests and correspondence: Dr. Barry J. Maron, Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, 920 East 28th Street, Suite 40, Minneapolis, Minnesota 55407
hcm.maron{at}mhif.org
OBJECTIVES
We sought to determine whether the development of left ventricular hypertrophy (LVH) can be demonstrated during adulthood in genetically affected relatives with hypertrophic cardiomyopathy (HCM).
BACKGROUND
Hypertrophic cardiomyopathy is a heterogeneous cardiac disease caused by mutations in nine genes that encode proteins of the sarcomere. Mutations in cardiac myosin-binding protein C (MyBPC) gene have been associated with age-related penetrance.
METHODS
To further analyze dormancy of LVH in patients with HCM, we studied, using echocardiography and 12-lead electrocardiography, the phenotypic expression caused by MyBPC mutations in seven genotyped pedigrees.
RESULTS
Of 119 family members studied, 61 were identified with a MyBPC mutation, including 21 genetically affected relatives (34%) who did not express the HCM morphologic phenotype (by virtue of showing normal left ventricular wall thickness). Of these 21 phenotype-negative individuals, 9 were children, presumably in the prehypertrophic phase, and 12 were adults. Of the 12 adults with normal wall thickness  12 mm (7 also with normal electrocardiograms), 5 subsequently underwent serial echocardiography prospectively over four to six years. Of note, three of these five adults showed development of LVH in mid-life, appearing for the first time at 33, 34 and 42 years of age, respectively, not associated with outflow obstruction or significant symptoms.
CONCLUSIONS
In adults with HCM, disease-causing MyBPC mutations are not uncommonly associated with absence of LVH on echocardiogram. Delayed remodeling with the development of LVH appearing de novo in adulthood, demonstrated here for the first time in individual patients with prospectively obtained serial echocardiograms, substantiates the principle of age-related penetrance for MyBPC mutations in HCM. These observations alter prevailing perceptions regarding the HCM clinical spectrum and family screening strategies and further characterize the evolution of LVH in this disease.
|
Abbreviations and Acronyms
| | DNA | = deoxyribonucleic acid | | ECG | = electrocardiogram or electrocardiographic | | HCM | = hypertrophic cardiomyopathy | | LV | = left ventricle or left ventricular | | LVH | = left ventricular hypertrophy | | MyBPC | = myosin-binding protein C | | SAM | = systolic anterior motion |
|
This article has been cited by other articles:
|
|
|
|
 
I. Christiaans, E. Birnie, I. M. van Langen, K. Y. van Spaendonck-Zwarts, J. P. van Tintelen, M. P. van den Berg, D. E. Atsma, A. T.J.M. Helderman-van den Enden, Y. M. Pinto, J.F. Hermans-van Ast, et al.
The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening
Eur. Heart J.,
December 16, 2009;
(2009)
ehp539v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Maron, J. R. Lesser, N. B. Schiller, K. M. Harris, C. Brown, and H. L. Rehm
Implications of Hypertrophic Cardiomyopathy Transmitted by Sperm Donation
JAMA,
October 21, 2009;
302(15):
1681 - 1684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Maron and C. Y. Ho
Hypertrophic cardiomyopathy without hypertrophy: an emerging pre-clinical subgroup composed of genetically affected family members.
J. Am. Coll. Cardiol. Img.,
January 1, 2009;
2(1):
65 - 68.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Martin, J. J. R. Reguero, M. G. Castro, E. Coto, E. Hernandez, A. Carro, D. Calvo, and C. M. de la Tassa
Hypertrophic cardiomyopathy and athlete's heart: a tale of two entities
Eur J Echocardiogr,
January 1, 2009;
10(1):
151 - 153.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Baggish, K. Yared, F. Wang, R. B. Weiner, A. M. Hutter Jr., M. H. Picard, and M. J. Wood
The impact of endurance exercise training on left ventricular systolic mechanics
Am J Physiol Heart Circ Physiol,
September 1, 2008;
295(3):
H1109 - H1116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Olivotto, M. S. Maron, C. Autore, J. R. Lesser, L. Rega, G. Casolo, M. De Santis, G. Quarta, S. Nistri, F. Cecchi, et al.
Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy
J. Am. Coll. Cardiol.,
August 12, 2008;
52(7):
559 - 566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Basavarajaiah, M. Wilson, G. Whyte, A. Shah, W. McKenna, and S. Sharma
Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening.
J. Am. Coll. Cardiol.,
March 11, 2008;
51(10):
1033 - 1039.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pelliccia, F. M. Di Paolo, F. M. Quattrini, C. Basso, F. Culasso, G. Popoli, R. De Luca, A. Spataro, A. Biffi, G. Thiene, et al.
Outcomes in Athletes with Marked ECG Repolarization Abnormalities
N. Engl. J. Med.,
January 10, 2008;
358(2):
152 - 161.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Hansen and N. Merchant
MRI of Hypertrophic Cardiomyopathy: Part I, MRI Appearances
Am. J. Roentgenol.,
December 1, 2007;
189(6):
1335 - 1343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Hansen and N. Merchant
MRI of Hypertrophic Cardiomyopathy: Part 2, Differential Diagnosis, Risk Stratification, and Posttreatment MRI Appearances
Am. J. Roentgenol.,
December 1, 2007;
189(6):
1344 - 1352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pelliccia, F. M. Di Paolo, D. Corrado, C. Buccolieri, F. M. Quattrini, C. Pisicchio, A. Spataro, A. Biffi, M. Granata, and B. J. Maron
Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes
Eur. Heart J.,
September 2, 2006;
27(18):
2196 - 2200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kubo, H. Kitaoka, M. Okawa, Y. Matsumura, N. Hitomi, N. Yamasaki, T. Furuno, J. Takata, M. Nishinaga, A. Kimura, et al.
Lifelong Left Ventricular Remodeling of Hypertrophic Cardiomyopathy Caused by a Founder Frameshift Deletion Mutation in the Cardiac Myosin-Binding Protein C Gene Among Japanese
J. Am. Coll. Cardiol.,
November 1, 2005;
46(9):
1737 - 1743.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Arad, M. Penas-Lado, L. Monserrat, B. J. Maron, M. Sherrid, C. Y. Ho, S. Barr, A. Karim, T. M. Olson, M. Kamisago, et al.
Gene Mutations in Apical Hypertrophic Cardiomyopathy
Circulation,
November 1, 2005;
112(18):
2805 - 2811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rickers, N. M. Wilke, M. Jerosch-Herold, S. A. Casey, P. Panse, N. Panse, J. Weil, A. G. Zenovich, and B. J. Maron
Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy
Circulation,
August 9, 2005;
112(6):
855 - 861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Maron, J.G. Seidman, and C. E. Seidman
Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy
J. Am. Coll. Cardiol.,
December 7, 2004;
44(11):
2125 - 2132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Maron, B. R. Chaitman, M. J. Ackerman, A. Bayes de Luna, D. Corrado, J. E. Crosson, B. J. Deal, D. J. Driscoll, N.A. M. Estes III, C. G. S. Araujo, et al.
Recommendations for Physical Activity and Recreational Sports Participation for Young Patients With Genetic Cardiovascular Diseases
Circulation,
June 8, 2004;
109(22):
2807 - 2816.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, F. J. Ten Cate, et al.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
J. Am. Coll. Cardiol.,
November 5, 2003;
42(9):
1687 - 1713.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, et al.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
Eur. Heart J.,
November 1, 2003;
24(21):
1965 - 1991.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Alders, R. Jongbloed, W. Deelen, A. van den Wijngaard, P. Doevendans, F. Ten Cate, V. Regitz-Zagrosek, H.-P. Vosberg, I. van Langen, A. Wilde, et al.
The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands
Eur. Heart J.,
October 2, 2003;
24(20):
1848 - 1853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Woo, H Rakowski, J C Liew, M-S Zhao, C-C Liew, T G Parker, M Zeller, E D Wigle, and M J Sole
Mutations of the {beta} myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis
Heart,
October 1, 2003;
89(10):
1179 - 1185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Maron, S. A. Casey, R. G. Hauser, and D. M. Aeppli
Clinical course of hypertrophiccardiomyopathy with survival to advanced age
J. Am. Coll. Cardiol.,
September 3, 2003;
42(5):
882 - 888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Garcia-Castro, J. R. Reguero, A. Batalla, B. Diaz-Molina, P. Gonzalez, V. Alvarez, A. Cortina, G. I. Cubero, and E. Coto
Hypertrophic Cardiomyopathy: Low Frequency of Mutations in the {beta}-Myosin Heavy Chain (MYH7) and Cardiac Troponin T (TNNT2) Genes among Spanish Patients
Clin. Chem.,
August 1, 2003;
49(8):
1279 - 1285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Konno, M. Shimizu, H. Ino, T. Matsuyama, M. Yamaguchi, H. Terai, K. Hayashi, T. Mabuchi, M. Kiyama, K. Sakata, et al.
A novel missense mutation in the myosin binding protein-C gene is responsible for hypertrophic cardiomyopathy with left ventricular dysfunction and dilation in elderly patients
J. Am. Coll. Cardiol.,
March 5, 2003;
41(5):
781 - 786.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Frustaci, M. Pieroni, and C. Chimenti
Late-onset primary LVH HCM versus cardiac fabry variant
J. Am. Coll. Cardiol.,
April 17, 2002;
39(8):
1405 - 1406.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Maron, J. G. Seidman, and C. E. Seidman
Late-onset primary LVHHCM versus cardiac fabry variant: reply
J. Am. Coll. Cardiol.,
April 17, 2002;
39(8):
1406 - 1406.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Maron
Hypertrophic Cardiomyopathy: A Systematic Review
JAMA,
March 13, 2002;
287(10):
1308 - 1320.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Marian
On genetic and phenotypic variability of hypertrophic cardiomyopathy: nature versus nurture
J. Am. Coll. Cardiol.,
August 1, 2001;
38(2):
331 - 334.
[Full Text]
[PDF]
|
|
|
|
